News | November 25, 2025
Abbott to acquire Exact Sciences for $21 billion
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
